Pliant Therapeutics Announces Research Collaboration with Cleveland Clinic to Develop New Disease Targets for Gastrointestinal Fibrosis

Posted On: September 6, 2018

SOUTH SAN FRANCISCO, CA — September 6, 2018 — Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that they have entered into a multi-year joint research collaboration with Cleveland Clinic to accelerate the discovery of potential disease targets for gastrointestinal fibrosis.

Read More

Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis

Posted On: August 6, 2018

SOUTH SAN FRANCISCO, CA — August 6, 2018 — Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company’s anti-fibrotic lead compound, PLN-74809, for the treatment of idiopathic pulmonary fibrosis (IPF).

Read More

Pliant Therapeutics Raises $62 Million in Series B Financing to Advance Therapies for Fibrotic Diseases

Posted On: July 16, 2018

SOUTH SAN FRANCISCO, CA — July 16, 2018 — Pliant Therapeutics, Inc. today announced that it has raised $62 million in a Series B financing. The funds will support the initiation and proof-of-concept clinical trials in idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), as well as ongoing drug discovery programs targeting other fibrotic […]

Read More

Pliant Therapeutics Presents Idiopathic Pulmonary Fibrosis Biomarker Discovery Research at American Thoracic Society 2018 International Conference

Posted On: May 22, 2018

SAN DIEGO — May 22, 2018 — Pliant Therapeutics, Inc. today presents at the American Thoracic Society 2018 International Conference a new approach to identify novel biomarkers to improve diagnosis, selection and assessment of treatments for Idiopathic Pulmonary Fibrosis (IPF). Company scientists and research collaborators successfully integrated tissue and plasma proteomics approaches to enhance detection […]

Read More

Pliant Therapeutics Appoints Hoyoung Huh as Chairman and Éric Lefebvre as Chief Medical Officer

Posted On: May 8, 2018

REDWOOD CITY, Calif., May 8, 2018 /PRNewswire/ — Pliant Therapeutics, Inc., a company focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases, today announced that Hoyoung Huh, M.D., Ph.D., has been appointed chairman of the board of directors and Éric Lefebvre M.D. has joined the company as chief medical officer. The appointments augment […]

Read More

Pliant to Present at the 38th Annual Cowen Healthcare Conference

Posted On: March 6, 2018

REDWOOD CITY, Calif. – March 6th, 2017 –Pliant Therapeutics, Inc., a company focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases, announced today that President and Chief Executive Officer, Bernard Coulie, M.D. Ph.D., will present at the 38th Annual Cowen Healthcare Conference being held in Boston, MA from March 12th – 14th, 2018.

Read More

Pliant Appoints Katerina Leftheris, Ph.D., as Vice President of Chemistry and John Curnutte, M.D., Ph.D. to the Board of Directors

Posted On: September 26, 2017

Redwood City, Calif. – September 26, 2017 – Pliant Therapeutics, Inc., a company focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases, announced today that Katerina Leftheris, Ph.D., will join the company as vice president of chemistry and John Curnutte, M.D., Ph.D., will be appointed to the board of directors.

Read More

Pliant Therapeutics Expands Leadership Team

Posted On: April 28, 2016

Redwood City, Calif. – April 28, 2016 – Pliant Therapeutics, Inc., a company focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases, today announced three leadership team appointments. Hans Hull, J.D., has joined the company as chief business officer, Patrick Andre, Ph.D., has been named vice president of biology and Randall Halcomb, Ph.D., […]

Read More